Published in final edited form as:

Prostaglandins Other Lipid Mediat. 2017 September ; 132: 59–68. doi:10.1016/j.prostaglandins.2017.01.003.

Hyperfiltration-Associated Biomechanical Forces in Glomerular Injury and Response: Potential Role for Eicosanoids

Mukut Sharma^{a,b,*}, Ram Sharma^a, Ellen T. McCarthy^b, Virginia J. Savin^{a,b}, and Tarak Srivastava^{a,c}

^aMBRF and Research Service, Kansas City VA Medical Center, Kansas City, MO, USA

^bKidney Institute, University of Kansas Medical Center, Kansas City, KS, USA

^cSection of Nephrology, Children's Mercy Hospital and University of Missouri at Kansas City, Kansas City, MO, USA

Abstract

Hyperfiltration is a well-known risk factor in progressive loss of renal function in chronic kidney disease (CKD) secondary to various diseases. A reduced number of functional nephrons due to congenital or acquired cause(s) results in hyperfiltration in the remnant kidney. Hyperfiltration-associated increase in biomechanical forces namely pressure-induced tensile stress and fluid flow-induced shear stress (FFSS) determine cellular injury and response. We believe the current treatment of CKD yields limited success because it largely attenuates pressure-induced tensile stress changes but not the effect of FFSS on podocytes. Studies on glomerular podocytes, tubular epithelial cells and bone osteocytes provide evidence for a significant role of COX-2 generated PGE₂ and its receptors in response to tensile stress and FFSS. Preliminary observations show increased urinary PGE₂ in children born with a solitary kidney. FFSS-induced COX2-PGE₂-EP₂ signaling provides an opportunity to identify targets and, for developing novel agents to complement currently available treatment.

Keywords

Hyperfiltration; Fluid flow shear stress; Tensile stress; Podocytes; Prostaglandin E₂; Prostanoid receptors

*Address for Correspondence: Mukut Sharma, MBRF and Research Service, Kansas City VA Medical Center, F2-120, Research Building, 4801 E. Linwood Blvd, STOP 151, Kansas City, MO 64128 USA, Tel: 816-861-4700 extn. 56626, Mukut.Sharma@va.gov.

Conflict of interest

Authors do not have any conflict of interest to declare regarding the contents of this article. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Glomerular hyperfiltration is considered to be a major risk factor in progressive loss of renal function in chronic kidney disease (CKD) patients. Despite decades of familiarity with the concept [1], the mechanical and rheological aspects of glomerular hyperfiltration remain unclear. Specifically, the role of hyperfiltration-associated increase in biomechanical forces needs to be explored in the context of glomerular intra-capillary space and extra-capillary Bowman's space. Cells of these two compartments namely capillary endothelial cells and podocytes in Bowman's space and the glomerular basement membrane constitute the glomerular filtration barrier. The glomerular filtration barrier is a complex structure that facilitates a close interaction between endothelial cells in the glomerular capillary lumen and podocytes in Bowman's space. The GBM with its porous structure provides a spatial separation and functional connectivity between the endothelial cells and podocytes [2,3]. Scanning electron micrographs show segments of capillary lumen with sieve-like arrangement of endothelial cells (Figure 1A) and interdigitated foot processes of podocytes that cover the capillary (Figure 1B). Such multicomponent architecture (Figure 1) of the filtration barrier generates the ultrafiltrate under physiological conditions withstanding much higher capillary pressures compared to non-glomerular capillaries. However, the changes in biomechanical forces under physiological or pathological conditions are not well-understood. Each component of the filtration barrier is important to maintain barrier function. Mesangial cells for their close interaction with their close interaction with endothelial cells and podocytes [4,5] and the GBM for its role as a matrix for endothelial cells and podocytes as well as a barrier [6–8]. The significance of capillary endothelial cells in glomerular function is also discussed in excellent reviews [9–11].

Effect of hyperfiltration-associated increase in fluid flow on non-endothelial cells such as podocyte may also have significant consequences on cellular integrity and in onset of glomerular dysfunction. While defects and/or damage to any component of the filtration barrier may compromise its function, podocytes are especially highly vulnerable to hyperfiltration as outlined here [12]. Hyperfiltration causes damage to podocyte structure and function indirectly through increase in capillary stretch as well as directly through elevated fluid flow shear stress (FFSS).

Of the two biomechanical forces associated with hyperfiltration, effects of pressure-induced tensile stress are more familiar and better understood because of extensive work in the past on renal blood flow, glomerular capillary pressure and systemic blood pressure to address the gradual loss of glomerular function. Indeed, the significance of glomerular capillary pressure and glomerular hypertension defined the role for renin angiotensin aldosterone system (RAAS) [1,13]. Renin, a product of the cells of the juxtaglomerular apparatus, activates the RAAS by converting angiotensinogen to angiotensin II (ANG II) in response to sympathetic activity and low blood pressure or sodium. Juxtaglomerular structures and their function continue to remain significant for ongoing research evidenced by recent reviews on the subject [14–16]. Previous work related to the RAAS resulted in the development of mainstream drugs such as angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEI) for treating hypertension that are also used to control pressure-related hyperfiltration-mediated renal dysfunction. These drugs are effective in delaying the

progression of CKD in some but not all kidney diseases. On the other hand, changes in glomerular cells (podocytes) caused by hyperfiltration-mediated increase in ultrafiltrate flow have not been targeted to treat renal dysfunction. Technical advances for studying biomechanical forces and a better understanding of podocyte biology have encouraged investigations into additional mechanisms to further improve the outcomes in patients with CKD.

This brief review outlines the significance of biomechanical forces in hyperfiltration with special reference to the increasing recognition of the effects of FFSS. We summarize results from studies on podocytes and other epithelial cells to distinguish effects of pressure-induced tensile stress and flow-induced shear stress on PGE₂, prostanoid receptors and key elements of their signaling pathway. Preliminary studies show that changes in urinary PGE₂ and other eicosanoids may be useful indicators to follow progression of CKD. Recent findings in renal tubular epithelial cells and bone osteocytes are provided as examples to demonstrate similarities in the mechanism(s) of the effect of biomechanical forces across different cell systems. The review summarizes the recent findings on the differential effects of biomechanical forces in glomerular dysfunction viewed through eicosanoid-mediated changes in podocytes. Considering the mechanism of hyperfiltration-induced injury of podocytes in terms of FFSS, hitherto unaddressed in the mainstream literature, will likely provide new directions for future investigations and drug development.

2. Single nephron glomerular filtration rate (SNGFR) and hyperfiltration

Approximately 1 million nephron units in each human kidney extract fluid from ~1500 liters of blood in 24 hours from glomerular capillary and generate ~180 liters ultrafiltrate into the Bowman's compartment. The ultrafiltrate is then processed down to ~1.5 liters in the tubular compartment and excreted as urine. Thus, plasma filtration in each glomerulus i.e. single nephron glomerular filtration rate (SNGFR) is a key indicator of renal function. SNGFR is determined by ultrafiltration coefficient (K_f), a product of total filtration area and hydraulic permeability (L_p) as well as net ultrafiltration pressure (P_{UF}). P_{UF} represents the difference between the net integrated hydraulic pressure and net plasma oncotic pressure [17].

An adaptive increase in SNGFR is immediately observed after unilateral nephrectomy that decreases the number of functional nephrons by half and results in increased blood flow, increased glomerular capillary pressure (P_{GC}) and filtration area [18] in the remnant functional kidney. Persistent adaptive hyperfiltration may become maladaptive and contribute to glomerular injury which, in turn, further propagates and exacerbates the magnitude of hyperfiltration. Hyperfiltration remains a loosely defined term but threshold levels of glomerular filtration rate (GFR) between 90.7 to 175 ml/min/1.73 m² with a median value of 135 ml/min/1.73 m² are reportedly indicate hyperfiltration [19,20]. Increased SNGFR entails greater ultrafiltrate flow through Bowman's space. Consequently, both pressure and flow related mechanical forces are relevant for the present discussion.

3. Biomechanical forces associated with hyperfiltration

Biomechanical forces generally connote musculoskeletal structure-function. Forces associated with fluid mechanics have been largely studied in terms of blood/gas flow-related pressure and shear. Plasma filtration in renal glomeruli exemplifies a unique interaction between blood flow in vasculature and ultrafiltrate flow in non-vascular space i.e. Bowman's space. Here, blood flow in the capillary indirectly affects podocytes. Capillary pressure generates tensile stress on capillary wall while plasma fluid filters into Bowman's space as the ultrafiltrate. Next, ultrafiltrate flow within Bowman's space directly exerts FFSS on podocytes (a.k.a. visceral epithelial cells) localized in Bowman's space (Figure 1C). Basal tensile stress and FFSS are integrated with physiological glomerular filtration but a decrease in the number of functional nephrons in CKD induces hyperfiltration in the remnant functional nephrons with a parallel rise in both tensile stress and FFSS. Glomerular hyperfiltration provides an interesting study of the temporal relationship between tensile stress and FFSS *vis-a-vis* their effects on podocytes.

(A) Tensile stress

Blood flow through capillary loops generates force radially at 90° to the direction of flow causing capillary wall stretch that radiates to podocyte foot processes attached to the GBM that covers the outer aspect of the capillary. To study the effect of experimental stretch, cells are grown on the flexible surface of specially designed petri dishes and subjected to computer-controlled application of vacuum generate uniaxial or biaxial stretch (Flexcell International Corporation, Burlington NC) [21], hydrostatic pressure [22], hypo-osmotic stretch [23], or magnetic pull to iron-coated cells [24].

(B) Fluid flow shear stress (FFSS)

Ultrafiltrate flow from capillary to the proximal tubule causes on major processes and cell bodies of podocytes in Bowman's space. To study the effect of experimental FFSS, cells are grown on glass slides and subjected to a fluid column of defined viscosity and dimensions. Thus, under defined conditions, flow rate is the only determinant of FFSS. The nature of the fluid column can be designed to deliver laminar, pulsatile or oscillating shear stress. Commercially available equipment can be used for treating multiple slides simultaneously (Streamer System, Flexcell Corporation). We have developed a special flow chamber for studies using FFSS-treated isolated glomeruli [25].

4. Hyperfiltration and arachidonic acid metabolites

Arachidonic acid metabolites are key regulators of renal blood flow, GFR, salt and water absorption, and renin secretion from the juxtaglomerular apparatus in kidneys [26, 27, 28,29]. Cyclooxygenases 1 and 2 (COX-1, COX-2), lipoxygenases (LOX) and cytochrome P450 (CYP2 epoxigenases and CYP4 ω -hydroxylases) generate prostaglandins, leukotrienes and epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs), respectively. Isoprostanes, prostaglandin-like eicosanoids, are formed by free radical-catalyzed peroxidation of arachidonic acid. Among these, PGE₂ has been found to have significant role in cellular response to hyperfiltration-mediated changes.

PGE₂ is generated from arachidonic acid by COX-1 and COX-2 activities. COX-1 is expressed constitutively whereas COX-2 is generally an inducible enzyme [30]. Podocytes express both COX-1 and COX-2 [31,32] and, we found that the COX2-PGE₂-EP₂ axis plays an important role in hyperfiltration-mediated glomerular injury in mouse models of solitary kidney as well as in cultured podocytes [25, 33]. PGE₂ is the major prostanoid under physiological conditions and interacts with four E-prostanoid (EP) receptors that have been cloned and characterized in both human and mouse [34,35].

Figure 2 summarizes the expression and functions of PGE₂ receptors EP₁-EP₄. EP₁ mRNA is restricted to kidney, lung and stomach [36]; EP₂, mainly found in vascular compartment of the kidney, and is induced in response to stimuli [34] while EP₃ and EP₄ are widely distributed [37,38]. In mouse kidneys, EP₁ is localized to the collecting ducts from the cortex to the papilla, EP₂ to glomeruli and arterioles, and EP₃ to tubules of outer medulla and the cortex [38,39]. Renal cells such as podocytes simultaneously express several EP receptors, and their relative levels determine the overall cellular response. Mouse podocytes express three of the four receptors for PGE₂ namely, EP₁, EP₂ and EP₄ [25]. In podocytes, basal expression of EP₄ is higher compared to that of EP₂ [25, 40]. While EP₄ expression was found to increase in response to tensile stress [10], we found that FFSS results in increased expression of EP₂ not EP₄ [25]. Previous studies identified expression of EP₂ in mesangial cells and infiltrating cells [41,42].

Pharmacological and gene targeting techniques have been used for determining the role of PGE₂ receptors [43]. Reported findings seem to vary. PGE₂ receptors are G-protein coupled proteins. EP₁ is coupled to calcium mobilization, EP₂ and EP₄ are linked to G_s protein, and EP₃ to G_i protein [34, 39]. EP₂ stimulates adenylate cyclase while both EP₂ and EP₄ cause vasodilatation of mouse afferent arteriole and buffer vasoconstrictor effects of EP₁ and EP₃ [44]. In addition, EP₄ mediates renin release [45]. EP₂ knock-out (KO) mice develop salt sensitive hypertension [46]. An anti-apoptotic/pro-survival role of EP₂ receptors have been implicated in renal cysts in ADPKD [47]. Glomerular size is reduced in EP₄, EP₂ or EP₁ deficient mice emphasizing the importance of PGE₂ in early postnatal period [48]. On the other hand EP₄ null mice were found protected from the injurious effects of 5/6 nephrectomy [49]. Prostacyclin receptor KO mice have no phenotype [50] but prostacyclin synthase KO mice have elevated levels of PGE₂ and a renal phenotype with cysts, sclerosis and vascular changes [51]. Although the foregoing section summarizes known changes potentially mediated by each receptor, the role of each receptor appears to be influenced by several factors including cell-type, study model and experimental conditions. These factors seem to result in overlapping and sometimes contradictory findings. Thus, assigning a definite role for each receptor would require validation in the context of specific disease model and experimental settings including gene deletion.

While tensile and shear stress involve distinct mechanisms, interactions between key molecules involved in pressure regulation and shear-induced add another level of complexity. Release of renin was found to be stimulated by COX-2 and PGE₂ mediated by EP₄ [45]. EETs and HETEs formed by the CYP450 enzymes interact with ANG II [52,53,54]. These findings suggest a significant cross-talk and modulatory interaction between eicosanoids and the RAAS in glomerular function. Likewise, similarities,

differences and cross-talk between EP receptors are also indicated by their effects on blood pressure and fertility. Although both EP₂ and EP₄ are G_s-coupled receptor proteins, they are differentially expressed in tissues, and their responses to stimuli are diverse. Additionally, genetic background, techniques used for gene deletion, sex hormones may influence the observed effects of PGE₂ receptors [55].

5. Effect of biomechanical forces on podocytes and PGE₂ as a mediator of fluid flow shear stress in podocytes

Podocytes provide the most structural resistance to the passage of plasma proteins from blood into urine. Podocytes are large terminally-differentiated epithelial cells localized in Bowman's space. Podocytes are characterized by an elaborate actin cytoskeleton and associated proteins such as nephrin, podocin, synaptopodin and podoplanin. With the cell body lies freely exposed within the Bowman's space, podocytes anchor on the GBM-covered capillary loops through primary processes that branch into foot processes and form slit pore junctions by interdigitating with foot processes from adjacent podocytes. Slit pore junctions restrict the passage of plasma macromolecules into Bowman's space (Figure 1C) [56]. The low/absent mitotic activity, large cell body, location in Bowman's space and vulnerability to tensile stress and FFSS make intact podocytes a critical but fragile component of the glomerular barrier function [57,58].

Recent reports from others have emphasized the significance of podocyte vulnerability to persistent capillary stretch and FFSS. Kritz and Lemley observed that capillary stretch is largely experienced at slit junctions between foot processes. In parallel, the cell body and primary processes of podocytes provide large area for sensing and transmitting the effects of FFSS which causes structural and functional changes within the cells. Increased biomechanical forces associated with hyperfiltration may contribute to podocyte detachment [59].

(A) Potential temporal difference in tensile stress and FFSS

Based on results from cell culture and animal models we have proposed that shear stress on podocytes due to increased ultrafiltrate flow is an important component of hyperfiltration-induced glomerular injury [4,25,33,60]. Thus, hyperfiltration can be visualized as a continuum with its early effects mediated by shear stress due to increased ultrafiltrate.

Persistent increase in tensile stress gradually overcomes impedance posed by the GBM and increasingly adds to the effects of hyperfiltration [Figure 3]. Other investigators have also emphasized the significance of shear stress in damage and loss of podocytes [59,61]. It is noteworthy that children born with a solitary kidney generally develop hypertension, albuminuria and/or decreased eGFR during late adolescence/young adulthood suggesting that FFSS drives the early loss of glomerular function in these children.

Such observations raise the possibility that early effects of hyperfiltration in some conditions may be largely due to effects of FFSS on podocytes. Endothelial fenestrae and GBM may, in part, dampen the transmission of capillary stretch before it reaches podocytes. Thus, capillary stretch during early hyperfiltration may cause insignificant tensile stress to

podocyte structures covering the capillary. This would imply that tensile stress makes a significant impact on podocytes only at later stages when capillary stretch overcomes the impedance posed by the GBM.

(B) Effects on podocyte morphology and proteins

Studies using cultured podocytes have begun to shed light on the differences between the mechanism(s) involved in the cellular effects of tensile stress and FFSS. Briefly, tensile stress decreases transverse actin fibers and increases radial fibers [57]. Tensile stress was shown to upregulate the expression of secreted protein acidic and rich in cysteine (SPARK i.e. Osteonectin) [62] and, of osteopontin [63,64]. Both proteins are mechanoprotective and decrease cell detachment caused by tensile stress. Cell stretch induces signaling by p38 MAPK, ERK1/2 and JNK but not AKT and GSK3 β [21,62, 64–68]. These observations require further investigation to confirm the role of and interaction(s) among signaling molecules.

In contrast, actin cytoskeleton forms a cortical ring structure in podocytes exposed to FFSS [33]. We also detected increased PGE₂ in FFSS-treated podocytes that was blocked by indomethacin [33]. FFSS increased COX-2 expression without altering COX-1 expression. However, FFSS resulted in upregulated the expression of EP₂ but not EP₄ [60].

(C) Effect on glomerular protein permeability

Podocytes are key constituents of the filtration barrier and changes in cellular structure would be reflected in filtration barrier characteristics. We used an *in vitro* assay to assess the effect of FFSS on glomerular albumin permeability as an indicator of filtration barrier characteristics. Further work to determine a direct effect of FFSS on intact glomerular filtration barrier showed increased albumin permeability in isolated glomeruli following FFSS [25]. These findings are in accordance with previously reported increase in albumin permeability in glomeruli incubated with PGE₂ [69]. Recent updates show that COX2-PGE₂-EP₂ axis with the activation of AKT- GSK3 β - β catenin and c-src-PLD-mTOR are considered mediators of the effects of FFSS [61].

(D) Effects on signaling mediators

Other investigators showed that tensile stress activates arachidonic acid metabolism through upregulation of COX-2 expression without changing COX-1 expression. Induction of 1–8% stretch caused a small increase in cAMP levels that was enhanced by exogenous PGE₂. Parallel experiments showed that addition of PGE₂ to cells immediately after stretch also increased cAMP production. Tensile stress increased the expression of EP₄ receptor of PGE₂ [21,66,67]. Activation of Gq-coupled signaling was also found to result in podocyte injury [68]. These observations support the role of COX-2 and EP₄ in tensile stress-induced cellular signaling without an increase in PGE₂.

(E) Effects on mouse models

Observations on the role of COX2-PGE₂-EP₂ pathway using cultured cells and isolated glomeruli were confirmed in mouse models of hyperfiltration. We used two different models of reduced functional nephron mass namely, unilaterally nephrectomized mice and mice

born with low nephron number. Unilaterally nephrectomized sv129 mice as well as Os/+ mice born with low nephron number showed albuminuria and increased glomerular expression of COX-2 enzyme and PGE₂ receptor EP₂ proteins [25,60].

Thus, podocytes respond to tensile stress and FFSS using distinct receptors and signaling mechanisms involving PGE₂. Biomechanical forces have been extensively studied in endothelial cells for their role in homeostasis, vascular remodeling and cardiovascular diseases. Effects of biomechanical forces on endothelial cells summarized in books [e.g. 70, 71] are beyond the scope of this brief discussion. On the other hand, evidence for a role of PGE₂-initiated signaling in mechanotransduction of shear stress in other epithelial cells such as osteocytes in the bone and tubular epithelial cells in the nephron is currently accumulating in parallel with our findings using podocytes.

6. PGE₂ as a mediator of fluid flow shear stress in osteocytes

Osteocytes, epithelial cells derived from osteoblast lineage, are embedded in mineralized bone matrix and function as the major mechanosensory cells in bone tissue. Osteocytes, like podocytes, are terminally differentiated and express podoplanin. Cytoplasmic processes (dendrites) from osteocytes traverse within the canaliculi of mature bone and connect with other osteocytes and with cells on bone surface through adhesion molecules and gap junctions. Computational modeling suggests that FFSS causes greater deformation of intracellular structures compared to stretch in osteocytes [72].

Several molecules/pathways involving nitric oxide [73], ATP [74], intracellular calcium [75] and COX-2 [76] have been identified in osteocyte response to stress. One model outlines a release of PGE₂ via calcium fluxes involving integrins and the cytoskeleton [77]. Another model describes FFSS-induced release of ATP that binds to P2Y and P2X₇ purinoceptors resulting in Ca²⁺ mobilization and PGE₂ release, respectively [78].

As with podocytes, the effects of mechanical stretch and FFSS in osteocytes are mediated through distinct pathways [72]. FFSS on osteocytes results in increased production of PGE₂, and increased expression of COX-2 and EP₂ but not EP₄ [79]. FFSS-induced release of PGE₂ activates EP₂ in osteocytes leading to activation of the AKT-GSK3β-β-catenin pathway and, to a lesser degree, of the cAMP-PKA pathway [80–83]. Thus, osteocytes sense mechanical strain and release PGE₂ which acts in a paracrine/autocrine fashion to engage EP₂ followed by GSK-3β phosphorylation and inactivation resulting in increased intracellular β-catenin that is translocated to the nucleus.

Similarities between podocytes and osteocytes in their responses to FFSS suggest that PGE₂-EP₂-Wnt/β-catenin signaling maybe a conserved mechanism for responding to mechanical stress in wider biological systems.

7. PGE₂ as a mediator of flow-induced shear stress in renal tubular cells

As in podocytes, tensile stress and shear stress induce distinct effects on the tubular segment of the nephron. Biomechanical forces secondary to tubular flow regulate sodium and potassium transport in renal epithelial cells [84]. Increased tubular urine flow caused by

diuretics and extracellular isotonic volume expansion causes circumferential stretch and shear stress on tubular cells and induces segment-specific signaling changes. Increased flow in cortical collecting duct results in greater sodium reabsorption and potassium secretion into urine. Circumferential stretch applied to cortical collecting duct decreases PGE₂ release while FFSS increases PGE₂ [85,86]. FFSS but not stretch upregulates COX-2, neutral sphingomyelinase, endothelin, phospho-ERK and phospho-p38 in cortical collecting duct cells [85–89]. Cilia or microvilli act as mechanosensors of shear and alter intracellular calcium resulting in cPLA2 activation [88,90] in renal cortical collecting duct principal and intercalated cells [85,91]. In proximal tubular cells, cyclical stretch results in ERK-dependent release of arachidonic acid [92] and FFSS promotes cytoskeletal re-organization by redistributing stress fibers from the basolateral membrane to apical surface and forming new apical junctional complexes [93,94].

These studies on tubular cells also support the differences in the mechanism of tensile stress and shear stress. Here again, PGE₂ causes a significant change in cellular responses to shear stress. Thus, it is apparent that podocytes, osteocytes and tubular epithelial cells invoke COX2-PGE₂ in response to biomechanical forces. While EP₂-Wnt/ β -catenin signaling seem to be critical in podocyte and osteocytes, p38 MAPK and ERK signaling seems to be utilized by tubular epithelial cells. These examples serve to support the occurrence of a common mechanism of cellular response to biomechanical forces in diverse epithelial cells.

8. Hyperfiltration and eicosanoids in kidney disease

Loss of functional nephrons due to developmental defects, hereditary disorders, surgical ablation, kidney donation, acute kidney injury and systemic diseases results in hyperfiltration leading to further damage to and loss of functional nephrons. Thus, adaptive hyperfiltration begets more hyperfiltration and eventually becomes maladaptive and leads to progression of CKD (Figure 4). Glomerular hyperfiltration is considered to be a major factor in renal injury from diabetes, hypertension and obesity, and a contributing factor in secondary focal segmental glomerulosclerosis [19]. The following paragraphs summarize the significance of hyperfiltration and eicosanoids in animal models and human diseases.

Animal models are commonly used to study the effect of hyperfiltration on glomerular function and renal disease. Several factors such as genetic characteristics, experimental gene manipulations, target cells and surgical manipulations need to be considered for selecting appropriate models to study expression and function of each receptor type [95–98]. Rat and mouse models have been used extensively to determine changes in arachidonic acid metabolism in models of acute and chronic kidney diseases. Synthesis of PGE₂, prostacyclin (PGI₂) and expression of COX-2 are increased in animal models of glomerular hyperfiltration, including subtotal nephrectomy [1,99–107], high protein intake [108,109], diabetes [110–116], hypertension [1,113,117] and obesity [109, 118–120]. A recent review suggests that microsomal prostaglandin E synthase (mPGES-1) contributes to reduction in renal function, urine concentrating ability and elevation in BP [121]. Renal function may also be affected by treating many of the conditions mentioned. For example, sodium glucose co-transporter 2 (SGL T2) inhibitors used for treating type 2 diabetes may benefit renal function through a slight reduction in blood pressure [122].

(A) Congenital anomalies of the kidney and urinary tract (CAKUT)

Hyperfiltration appears to be the main reason of initial progression of CKD in children born with a solitary kidney or other CAKUT. Between 20% and 40% of children born with a solitary kidney develop ESRD as young adults, with manifestations of renal injury starting only at ~15 years of age [123,124]. Preliminary work in our laboratory using liquid chromatography-mass spectrometry analysis showed increased urinary PGE₂ (p=0.14) and decreased PGI₂ (p=0.04) in this small group of children with a solitary kidney (Table 1).

(B) Surgical resection resulting in solitary kidney

Fifteen healthy humans had a significant increase in GFR, effective renal plasma flow (ERPF), urine flow, sodium and potassium excretions, urinary excretion rate of PGE₂ and 6-keto prostaglandin F1 alpha (6-keto PGF1 alpha) in the remaining kidney (p<0.01) at 10 days after unilateral nephrectomy. Indomethacin administered at 75 mg/day for 3 days abolished the increase in GFR, ERPF and sodium excretion with reduced urinary excretion rate of PGE₂ and 6-keto PGF1 alpha but not the increase in urine flow and potassium excretion. These findings suggest that renal prostaglandins may play a role in renal functional adaptation following unilateral nephrectomy [125].

(C) Kidney donors

Approximately a third of all renal transplants are obtained from living donors [126]. Currently there are ~50,000 individuals who have donated one kidney and their number increases each year by ~5000 [127,128]. Kidney donors have increased risk of developing end stage renal disease (ESRD) with a median period of ~15 years after kidney donation [129]. This suggests that the conditions remain benign for a long time and that younger donors (<35 years) would be at a greater lifetime risk for ESRD [130,131]. Likewise, hyperfiltration would be a key determinant of long term outcome of renal function in transplant recipients who face additional risk due to potential adverse effects of post-transplantation medications.

Examples from animal studies and observations in human subjects suggest that eicosanoids play a role in mediating the effects of biomechanical forces associated with hyperfiltration that remains a serious challenge in the management of kidney disease.

9. Amelioration of hyperfiltration-induced glomerular dysfunction

COX inhibitors, prostanoids or their analogs have been used for minimizing the effect of hyperfiltration in different settings including hypertension and diabetes.

(A) Treatments to modulate prostanoid levels

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce intractable proteinuria [132]. However, NSAIDs also cause loss of renal function. Therefore, these drugs are not popular as first or second line of treatment. Proteinuria is reduced by COX inhibition from NSAIDs drugs, and this improvement is associated with decreased PGE₂ excretion [133,134]. NSAIDs that reduce renal PGE₂ excretion also decrease proteinuria, whereas sulindac which does not influence PGE₂ levels has no impact [135–137].

Prostacyclin analog Beraprost-Na delayed the doubling of creatinine in 5/6 rat nephrectomy model [138], anti-GBM model [138,139] and has a possible effects in humans with chronic glomerulonephritis [140]. Urinary PGI₂ showed no relationship with the development of hemolytic uremic syndrome and was not protective [141]. PGE₁ infusion reduced albuminuria and proteinuria in diabetic nephropathy in six studies included in Cochrane Review [142]. PGE₁ infusion was not helpful in 8 adults with CKD [143] or in 9 adults with GN [144] but PGE₁ with ACEI was helpful in 52 adults with CKD [145].

(B) Treatments directed at the renin angiotensin aldosterone system (RAAS)

RAAS antagonists are the major class of drugs currently used to treat hyperfiltration-mediated injury in progression of CKD. However, ACEI and ARBs were not effective in delaying the progression of disease in children with CAKUT in ItalKid study [146]. RAAS blockade is also not the standard of care in children with CAKUT as evident from the NIH CKiD study where fewer than 50% of children were on the treatment [147]. Thus, there is a need to further understand the basic mechanism of hyperfiltration that could complement the RAAS-mediated changes from early to late stages of the disease.

10. Summary

Hyperfiltration is considered a common underlying mechanism for progression of CKD associated with a number of diseases. Tensile stress and fluid flow shear stress are biomechanical forces associated with hyperfiltration. The effect of these biomechanical forces on glomerular podocytes and cellular mediators their effects are not clear. ACE inhibitors and ARBs are commonly used as renoprotective drugs to delay progression of CKD. However, these drugs are not favored for treating progression of CKD in children with a solitary kidney or transplant donors where hyperfiltration is the dominant cause of renal dysfunction. Therefore, effects of tensile stress and shear stress on podocytes need to be addressed for a comprehensive approach to treat CKD. Several lines of evidence demonstrate that tensile stress and shear stress invoke distinct mechanisms in podocytes and other cells. In this regard, we have shown that fluid flow shear stress upregulates COX2-PGE₂-EP₂ in podocytes. Similar signaling mechanisms appear to mediate the effect of biomechanical forces in other epithelial cells as well. Further research on tensile and shear stress-induced cellular pathways that address interaction between PGE₂ receptors may lead to identification of additional targets for novel treatments that will complement the current RAAS therapy.

Acknowledgments

Authors wish to thank members of the laboratory who contributed to the research summarized here. We also acknowledge the contribution of a large number of investigators whose work could not be cited here. Space limits do not permit inclusion of references to all the work that helped our progress with the ideas discussed in this article.

Financial support

Research summarized here was supported by NIH-NIDDK R01DK107490, R01DK064969, R21DK00292588, VA BX001037, the Midwest Biomedical Research Foundation and the Kansas City VA Medical Center, Kansas City, MO.

References

1. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. *Kidney Int.* 1996; 49:1774–77. [PubMed: 8743495]
2. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. *Physiol Rev.* 2008; 88:451–87. [PubMed: 18391170]
3. Jarad G, Miner JH. Update on the glomerular filtration barrier. *Curr Opin Nephrol Hypertens.* 2009; 18:226–32. [PubMed: 19374010]
4. Schlöndorff D, Bernhard Banas B. The Mesangial Cell Revisited: No Cell Is an Island. *J Am Soc Nephrol.* 2009; 20:1179–1187. [PubMed: 19470685]
5. Ghayur MN, Krepinsky JC, Janssen LJ. Contractility of the renal glomerulus and mesangial cells: lingering doubts and strategies for the future. *Med Hypotheses Res.* 2008; 4:1–9. [PubMed: 22287940]
6. Yurchenco, PD. Cold Springs Harbor Perspectives. 2010. Basement Membranes: Cell Scaffoldings and Signaling Platforms.
7. Menon MC, Chuang PY, John He CJ. The Glomerular Filtration Barrier: Components and Crosstalk. *Int J Nephrol.* 2012; 2012:9. Article ID 749010. [org/10.1155/2012/749010](https://doi.org/10.1155/2012/749010).
8. Suh HH, Miner JH. The glomerular basement membrane as a barrier to albumin. *Nature Rev Nephrol.* 2013; 9:470–77. [PubMed: 23774818]
9. Haraldsson B, Nyström J, Deen WM. Properties of the Glomerular Barrier and Mechanisms of Proteinuria. *Physiol Rev.* 2008; 88:451–87. [PubMed: 18391170]
10. Satchell S. The role of the glomerular endothelium in albumin handling. *Nature Reviews Nephrology.* 2013; 9:717–25. [PubMed: 24080802]
11. Scott RP, Quaggin SE. The cell biology of renal filtration. *J cell Biol.* 2015; 209:199–210. [PubMed: 25918223]
12. Srivastava T, Celsi GE, Sharma M, et al. Fluid flow shear stress over podocytes is increased in the solitary kidney. *Nephrol Dial Transplant* 2014. 2014; 29:65–72.
13. Hostetter TH. Hyperfiltration and glomerulosclerosis. *Semin Nephrol.* 2003; 23:194–9. [PubMed: 12704579]
14. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. *J Am Soc Nephrol.* 2010; 21:1093–6. [PubMed: 20360309]
15. Peti-Peterdi J. Newly stemming functions of macula densa-derived prostanoids. *Hypertension.* 2015; 65:987–88. [PubMed: 25776068]
16. Vivette D, D'Agati VD, Chagnac A, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. *Nature Rev Nephrology.* 2016; 12:453–41. [PubMed: 27263398]
17. Pollak MR, Quaggin SE, Hoenig MP, et al. The Glomerulus: The sphere of influence. *Clin J Am Soc Nephrol.* 2014; 9:1461–69. [PubMed: 24875196]
18. Celsi G, Larsson L, Seri I, et al. Glomerular adaptation in uninephrectomized young rats. *Pediatr Nephrol.* 1989; 3:280–5. [PubMed: 2702105]
19. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. *Nat Rev Nephrol.* 2012; 8:293–300. [PubMed: 22349487]
20. Cachat F, Combescure C, Cauderay M, et al. A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. *Clin J Amer Soc Nephrol.* 2015; 10:382–9. [PubMed: 25568216]
21. Martineau LC, McVeigh LI, Jasmin BJ, et al. p38 MAP kinase mediates mechanically induced COX-2 and PG EP4 receptor expression in podocytes: implications for the actin cytoskeleton. *Am J Physiol Renal Physiol.* 2004; 286:F693–701. [PubMed: 14665434]
22. Coers W, Vos JT, Huitema S, et al. Biological alterations of rat podocytes cultured under basolateral hydrostatic pressure. *Pathobiology.* 1996; 64:222–32. [PubMed: 9031333]
23. Anderson M, Kim EY, Hagmann H, et al. Opposing effects of podocin on the gating of podocyte TRPC6 channels evoked by membrane stretch or diacylglycerol. *Am J Physiol Cell Physiol.* 2013; 305:C276–89. [PubMed: 23657570]

24. Glogauer M, Ferrier J. A new method for application of force to cells via ferric oxide beads. *Pflugers Arch.* 1998; 435:320–7. [PubMed: 9382948]
25. Srivastava T, Alon US, Cudmore PA, et al. Cyclooxygenase-2, prostaglandin E2 and prostanoid receptor EP2 in fluid flow shear stress mediated injury in solitary kidney. *Am J Physiol Renal Physiol.* 2014; 307:F1323–33. [PubMed: 25234310]
26. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. *Am J Physiol Renal Physiol.* 2001; 281:F1–11. [PubMed: 11399641]
27. Persson AE, Ollerstam A, Liu R, et al. Mechanisms for macula densa cell release of renin. *Acta Physiol Scand.* 2004; 181:471–4. [PubMed: 15283760]
28. Harris RC, Zhang MZ, Cheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. *Acta Physiol Scand.* 2004; 181:543–7. [PubMed: 15283769]
29. Arima S, Ito S. Role of renal eicosanoids in the control of intraglomerular and systemic blood pressure during development of hypertension. *Contrib Nephrol.* 2004; 143:65–76. [PubMed: 15248356]
30. FitzGerald GA. The choreography of cyclooxygenases in the kidney. *J Clin Invest.* 2002; 110:33–34. [PubMed: 12093885]
31. Komhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. *Am J Physiol.* 1997; 272:F460–8. [PubMed: 9140046]
32. Cheng H, Wang S, Jo YI, et al. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. *J Am Soc Nephrol.* 2007; 18:551–9. [PubMed: 17202413]
33. Srivastava T, McCarthy ET, Sharma R, et al. Prostaglandin E2 is crucial in the podocytes response to fluid flow shear stress. *J Cell Commun Signal.* 2010; 4:79–90. [PubMed: 20531983]
34. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. *Physiol Rev.* 1999; 79:1193–1226. [PubMed: 10508233]
35. Breyer MD, Davis L, Jacobson HR, et al. Differential localization of prostaglandin E receptor subtypes in human kidney. *Am J Physiol.* 1996; 270:F912–18. [PubMed: 8928854]
36. Watabe A, Sugimoto Y, Honda A, et al. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. *J Biol Chem.* 1993; 268:20175–8. [PubMed: 7690750]
37. Bhattacharya M, Peri K, Ribeiro-da-Silva A, Almazan G, Shichi H, Hou X, Varma DR. Localization of functional prostaglandin E2 receptors EP3 and EP4 in nuclear envelope. *J Biol Chem.* 1999; 274:15719–24. [PubMed: 10336471]
38. Sugimoto Y, Narumiya S. Prostaglandin E Receptors. *J Biol Chem.* 2007; 282:11613–17. [PubMed: 17329241]
39. Sugimoto Y, Namba T, Shigemoto R, et al. Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney. *Am J Physiol.* 1994; 266:F823–8. [PubMed: 8203567]
40. Breyer RM, Davis LS, Nian C, et al. Cloning and expression of the rabbit prostaglandin EP4 receptor. *Am J Physiol.* 1996; 270:F485–93. [PubMed: 8780252]
41. Bek M, Nusing R, Kowark P, et al. Characterization of prostanoid receptors in podocytes. *J Am Soc Nephrol.* 1999; 10:2084–93. [PubMed: 10505684]
42. Guan Y, Stillman BA, Zhang Y, et al. Cloning and expression of the rabbit prostaglandin EP2 receptor. *BMC Pharmacol.* 2002; 2:14. [PubMed: 12097143]
43. Breyer RM, Kennedy CR, Zhang Y, et al. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. *Ann N Y Acad Sci.* 2000; 905:221–31. [PubMed: 10818456]
44. Imig JD, Breyer MD, Breyer RM. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. *Am J Physiol Renal Physiol.* 2002; 283:F415–22. [PubMed: 12167591]
45. Nüsing RM, Treude A, Weissenberger C, et al. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. *J Am Soc Nephrol.* 2005; 16:2354–62. [PubMed: 15976003]

46. Kennedy CR, Zhang Y, Brandon S, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. *Nat Med.* 1999; 5:217–20. [PubMed: 9930871]
47. Elberg G, Elberg D, Lewis TV, et al. EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells. *Am J Physiol Renal Physiol.* 2007; 293:F1622–32. [PubMed: 17728378]
48. Frölich S, Olliges A, Kern N, et al. Temporal expression of the PGE 2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. *J Physiol Renal Physiol.* 2012; 303:F209–19.
49. Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. *J Am Soc Nephrol.* 2010; 21:1678–90. [PubMed: 20671216]
50. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. *Nature.* 1997; 388:678–82. [PubMed: 9262402]
51. Yokoyama C, Yabuki T, Shimonishi M, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. *Circulation.* 2002; 106:2397–403. [PubMed: 12403673]
52. Joly E, Seqqat R, Flamion B, et al. Increased renal vascular reactivity to ANG II after unilateral nephrectomy in the rat involves 20-HETE. *Am J Physiol Regul Integr Comp Physiol.* 2006; 91:R977–86.
53. McGiff JC, Ferreri NR, Carroll MA. The eicosanoid factor: a determinant of individuality of nephron segments. *J Physiol Pharmacol.* 2002; 53:525–32. [PubMed: 12512690]
54. Alonso-Galicia M, Maier KG, Greene AS, et al. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. *Am J Physiol Regul Integr Comp Physiol.* 2002; 283:R60–68. [PubMed: 12069931]
55. Austin S, FitzGerald GA. Not a mouse stirring: deletion of EP2 and love's labor's lost. *J Clin Invest.* 1999; 103:1481–82. [PubMed: 10359555]
56. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. *Physiol Rev.* 2003; 83:253–307. [PubMed: 12506131]
57. Endlich N, Kress KR, Reiser J, et al. Podocytes respond to mechanical stress in vitro. *J Am Soc Nephrol.* 2001; 12:413–22. [PubMed: 11181788]
58. Endlich N, Endlich K. The challenge and response of podocytes to glomerular hypertension. *Semin Nephrol.* 2012; 32:327–41. [PubMed: 22958487]
59. Kriz W, Lemley KV. A Potential role for mechanical forces in the detachment of podocytes and the progression of CKD. *J Am Soc Nephrol.* 2015; 26:258–69. [PubMed: 25060060]
60. Srivastava T, McCarthy ET, Sharma R, et al. Fluid flow shear stress upregulates prostanoid receptor EP2 but not EP4 in murine podocytes. *Prostaglandins Other Lipid Mediat.* 2013; 104–105:49–57.
61. Sekulic SP, Sekulic M. Rheological influence upon the glomerular podocyte and resultant mechanotransduction. *Kidney Blood Press Res.* 2015; 40:176–7. [PubMed: 25871438]
62. Durvasula RV, Shankland SJ. Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. *Am J Physiol Renal Physiol.* 2005; 289:F577–84. [PubMed: 16093428]
63. Endlich N, Sunohara M, Nietfeld W, et al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. *FASEB J.* 2002; 16:1850–2. [PubMed: 12354696]
64. Schordan S, Schordan E, Endlich K, et al. AlphaV-integrins mediate the mechanoprotective action of osteopontin in podocytes. *Am J Physiol Renal Physiol.* 2011; 300:F119–32. [PubMed: 21048023]
65. Eekhoff A, Bonakdar N, Alonso JL, et al. Glomerular podocytes: a study of mechanical properties and mechano-chemical signaling. *Biochem Biophys Res Commun.* 2011; 406:229–33. [PubMed: 21315064]
66. Faour WH, Thibodeau JF, Kennedy CR. Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes. *Cell Signal.* 2010; 22:1222–30. [PubMed: 20362052]
67. Janmey PA, Miller RT. Mechanisms of mechanical signaling in development and disease. *J Cell Sci.* 2011; 124:9–18. [PubMed: 21172819]

68. Wang L, Fields TA, Pazmino K, et al. Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury. *J Am Soc Nephrol*. 2005; 16:3611–22. [PubMed: 16267159]
69. McCarthy ET, Sharma M. Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. *Kidney Int*. 2002; 61:534–41. [PubMed: 11849393]
70. Gimbrone, MA. Mechanical Forces and the Endothelium (volume 6). In: Rubanyi, GM., editor. *The Endothelium Cell Research Series*. Harwood Academic Press; 2004.
71. Aranda-Espinoza, H., editor. *Mechanobiology of the endothelium*. CRC Press; 2015.
72. McGarry JG, Klein-Nulend J, Mullender MG, et al. A comparison of strain and fluid shear stress in stimulating bone cell responses- a computational and experimental study. *FASEB J*. 2005; 19:482–84. [PubMed: 15625080]
73. Klein-Nulend J, Semeins CM, Ajubi NE, et al. Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts - correlations with prostaglandin upregulation. *Biochem Biophys Res Commun*. 1995; 217:640–8. [PubMed: 7503746]
74. Genetos DC, Geist DJ, Liu D, et al. Fluid Shear-Induced ATP Secretion Mediates Prostaglandin Release in MC3T3-E1 Osteoblasts. *J Bone Min Res*. 2005; 20:41–49.
75. Jorgensen NR, Teilmann SC, Henriksen Z, et al. Activation of L-type Calcium Channels is Required for Gap Junction-mediated Intracellular Calcium Signaling in Osteoblastic Cells. *J Biol Chem*. 2003; 278:4082–6. [PubMed: 12446698]
76. Forwood MR. Inducible Cyclo-oxygenase (COX-2) Mediates the Induction of Bone Formation by Mechanical Loading In Vivo. *J Bone Miner Res*. 1996; 11:1688–93. [PubMed: 8915776]
77. Ajubi NE, Klein-Nulend J, Alblas MJ, et al. Signal transduction pathways involved in fluid flow-induced PGE2 production by cultured osteocytes. *Am J Physiol*. 1999; 276(1 Pt 1):E171–8. [PubMed: 9886964]
78. Li J, Liu D, Ke HZ, et al. The P2X7 Nucleotide receptor mediates skeletal mechanotransduction. *J Biol Chem*. 2005; 280:42952–9. [PubMed: 16269410]
79. Cherian PP, Cheng B, Gu S, et al. Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. *J Biol Chem*. 2003; 44:43146–56.
80. Kitase Y, Barragan L, Qing H, et al. Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the β -catenin and PKA pathways. *J Bone Miner Res*. 2010; 12:2657–68.
81. Xia X, Batra N, Shi Q, et al. Prostaglandin promotion of osteocyte gap junction function through transcriptional regulation of connexin 43 by glycogen synthase kinase 3/beta-catenin signaling. *Mol Cell Biol*. 2010; 1:206–19.
82. Kamel MA, Picconi JL, Lara-Castillo N, et al. Activation of β -catenin signaling in MLO-Y4 osteocytic cells versus 2T3 osteoblastic cells by fluid flow shear stress and PGE2: Implications for the study of mechanosensation in bone. *Bone*. 2010; 47:872–81. [PubMed: 20713195]
83. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. *Bone*. 2008; 42:606–15. [PubMed: 18280232]
84. Morimoto T, Liu W, Woda C, et al. Mechanism underlying flow stimulation of sodium absorption in the mammalian collecting duct. *Am J Physiol (Renal Physiol)*. 2006; 291:F663–9. [PubMed: 16638910]
85. Liu Y, Flores D, Carrisoza-Gaytán R, Rohatgi R. Cholesterol affects flow-stimulated cyclooxygenase-2 expression and prostanoid secretion in the cortical collecting duct. *Am J Physiol (Renal Physiol)*. 2015; 308:F1229–37. [PubMed: 25761882]
86. Carrisoza-Gaytan R, Liu Y, Flores D, et al. Effects of biomechanical forces on signaling in the cortical collecting duct (CCD). *Am J Physiol (Renal Physiol)*. 2014; 307:F195–204. [PubMed: 24872319]
87. Liu Y, Flores D, Carrisoza-Gaytán R, et al. Biomechanical regulation of cyclooxygenase-2 in the renal collecting duct. *Am J Physiol (Renal Physiol)*. 2014; 306:F214–23. [PubMed: 24226521]
88. Flores D, Liu Y, Liu W, et al. Flow-induced prostaglandin E2 release regulates Na and K transport in the collecting duct. *Am J Physiol (Renal Physiol)*. 2012; 303:F632–8. [PubMed: 22696602]

89. Flores D, Battini L, Gusella GL, et al. Fluid shear stress induces renal epithelial gene expression through polycystin-2-dependent trafficking of extracellular regulated kinase. *Nephron Physiol.* 2011; 117:27–36.
90. Weinbaum S, Duan Y, Satlin LM, et al. Mechanotransduction in the renal tubule. *Am J Physiol (Renal Physiol).* 2010; 299:F1220–36. [PubMed: 20810611]
91. Rohatgi R, Battini L, Kim P, et al. Mechanoregulation of intracellular Ca²⁺ in human autosomal recessive polycystic kidney disease cyst-lining renal epithelial cells. *Am J Physiol Renal Physiol.* 2008; 294:F890–9. [PubMed: 18256315]
92. Alexander LD, Alagarsamy S, Douglas JG. Cyclic stretch-induced cPLA2 mediates ERK 1/2 signaling in rabbit proximal tubule cells. *Kidney Int.* 2004; 65:551–63. [PubMed: 14717925]
93. Duan Y, Gotoh N, Yan Q, et al. Shear-induced reorganization of renal proximal tubule cell actin cytoskeleton and apical junctional complexes. *Proc Natl Acad Sci USA.* 2008; 105:11418–23. [PubMed: 18685100]
94. Alenghat FJ, Nauli SM, Kolb R, et al. Global cytoskeletal control of mechanotransduction in kidney epithelial cells. *Exp Cell Res.* 2004; 301:23–30. [PubMed: 15501441]
95. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. *Kidney Int.* 1992; 42:148–160. [PubMed: 1635344]
96. Ma L-J, Fogo AB. Model of robust induction of glomerulosclerosis in mice: Importance of genetic background. *Kidney Int.* 2003; 64:350–5. [PubMed: 12787428]
97. Zalup RK. The Os/+ mouse: A genetic animal model of reduced renal mass. *Am J Physiol.* 1993; 264:F53–60. [PubMed: 8430831]
98. Friedrich C, Endlich N, Kriz W, et al. Podocytes are sensitive to fluid shear stress in vitro. *Am J Physiol Renal Physiol.* 2006; 291:F856–65. [PubMed: 16684926]
99. Brenner BM. Nephron adaptation to renal injury or ablation. *Am J Physiol.* 1985; 249:F324–37. [PubMed: 3898871]
100. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. *Kidney Int Suppl.* 1997; 63:S124–27. [PubMed: 9407439]
101. Stahl RA, Kudelka S, Paravicini M, et al. Prostaglandin and thromboxane formation in glomeruli from rats with reduced renal mass. *Nephron.* 1986; 42:252–57. [PubMed: 3456090]
102. Nath KA, Chmielewski DH, Hostetter TH. Regulatory role of prostanoids in glomerular microcirculation of remnant nephrons. *Am J Physiol.* 1987; 252:F829–F837. [PubMed: 3578532]
103. Wang JL, Cheng HF, Zhang MZ, et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. *Am J Physiol.* 1998; 275:F613–F622. [PubMed: 9755133]
104. Sanchez PL, Salgado LM, Ferreri NR, et al. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. *Hypertension.* 1999; 34:848–53. [PubMed: 10523372]
105. Horiba N, Kumano E, Watanabe T, et al. Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney. *Nephron.* 2002; 91:134–41. [PubMed: 12021530]
106. Ots M, Troy JL, Rennke HG, et al. Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease. *Nephrol Dial Transplant.* 2004; 19:337–41. [PubMed: 14736956]
107. Babelova A, Jansen F, Sander K, et al. Activation of Rac-1 and RhoA Contributes to Podocyte Injury in Chronic Kidney Disease. *PLoS ONE.* 2013; 8:e80328.doi: 10.1371/journal.pone.0080328 [PubMed: 24244677]
108. Klahr S. Effects of protein intake on the progression of renal disease. *Ann Rev Nutr.* 1989; 9:87–108. [PubMed: 2669884]
109. Yao B, Xu J, Qi Z, et al. Role of renal cortical cyclooxygenase-2 expression in hyperfiltration in rats with high-protein intake. *Am J Physiol Renal Physiol.* 2006; 291:F368–74. [PubMed: 16597606]
110. O'Donnell MP, Kasiske BL, Keane WF. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. *FASEB J.* 1988; 2:2339–2347. [PubMed: 3282959]
111. Lopes GS, Lemos CCS, Mandarin-de-Lacerda CA, et al. Effect of unilateral nephrectomy on renal function of diabetic rats. *Histol Histopathol.* 2004; 19:1085–1088. [PubMed: 15375750]

112. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. *Clin Exp Pharmacol Physiol*. 2007; 34:36–41. [PubMed: 17201733]
113. Sasson AN, Cherney DZI. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. *World J Diabetes*. 2012; 3:1–6. [PubMed: 22253940]
114. Ruggenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in Type 2 Diabetes. *Diabetes Care*. 2012; 35:2061–68. [PubMed: 22773704]
115. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. *Nephrol Dial Transplant*. 2012; 27:1708–14. DOI: 10.1093/ndt/gfs037 [PubMed: 22431709]
116. Vallon V, Thomson SC. Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney. *Annu Rev Physiol*. 2012; 74:351–75. [PubMed: 22335797]
117. Herrera-Acosta J, Tapia E, Bobadilla NA, et al. Evaluating hyperfiltration with glycine in hypertensive rats with renal ablation. *Hypertension*. 1988; 11:133–7.
118. Hunley TE, Li-Jun Ma L-J, Kon V. Scope and Mechanisms of Obesity-Related Renal Disease. *Curr Opin Nephrol Hypertens*. 2010; 9:227–34.
119. Kanasaki K, Kitada M, Kanasaki M, et al. The biological consequences of obesity on the kidney. *Nephrol Dial Transplant*. 2013; 28(Suppl 4):iv1–7. DOI: 10.1093/ndt/gft098 [PubMed: 23743020]
120. Gai Z, Hiller C, Chin SH, et al. Uninephrectomy augments the effects of high fat diet-induced obesity on gene expression in mouse kidney. *Biochim Biophys Acta*. 2014; 1842:1870–78. [PubMed: 25016146]
121. Regner KR. Dual role of microsomal prostaglandin E synthase 1 in chronic kidney disease. *Hypertension*. 2012; 59:12–13. [PubMed: 22106400]
122. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation*. 2016; 134:752–72. [PubMed: 27470878]
123. Sanna-Cherchi S, Ravani P, Corbani V, et al. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. *Kidney Int*. 2009; 76:528–33. [PubMed: 19536081]
124. Westland R, Schreuder MF, Ket JC, et al. Unilateral renal agenesis: a systematic review on associated anomalies and renal injury. *Nephrol Dial Transplant*. 2013; 28:1844–55. [PubMed: 23449343]
125. Mizuiri S, Takano M, Hayashi I. Effect of prostaglandins on renal function in uninephrectomized humans. *Nephron*. 1993; 63:429–33. [PubMed: 8459878]
126. Grams ME, Sang Y, Levey AS, et al. Kidney-failure risk projection for the living kidney-donor candidate. *N Engl J Med*. 2016; 374:411–21. [PubMed: 26544982]
127. <http://optn.transplant.hrsa.gov/>
128. http://www.usrds.org/2015/view/v2_07.aspx
129. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. *JAMA*. 2014; 311:579–86. [PubMed: 24519297]
130. Gibney EM, parikh CR, Garg AX. Age, gender, race, and associations with kidney failure following living kidney donation. *Transplant Proc*. 2008; 40:1337–40. [PubMed: 18589100]
131. Steiner RW, Ix JH, Rifkin DE, et al. Estimating risk of de novo kidney diseases after living kidney donation. *Am J Transplant*. 2014; 14:538–44. [PubMed: 24612746]
132. Vogt L, Laverman GD, Navis G. Time for a comeback of NSAIDs in proteinuric chronic kidney disease? *Neth J Med*. 2010; 68:400–7. [PubMed: 21209465]
133. Vriesendorp R, Donker AJ, de Zeeuw D, et al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. *Am J Med*. 1986; 81:84–94. [PubMed: 3529951]
134. Vriesendorp R, de Zeeuw D, de Jong PE, et al. Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs. *Clin Nephrol*. 1986; 25:105–10. [PubMed: 3516475]

135. Golbetz H, Black V, Shemesh O, et al. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. *Am J Physiol.* 1989; 256:F44–F51. [PubMed: 2463770]
136. Vriesendorp R, Donker AJ, de Zeeuw D, et al. Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. *Am J Nephrol.* 1985; 5:236–242. [PubMed: 3901756]
137. Zambraski EJ, Dodelson R, Guidotti SM, et al. Renal prostaglandin E2 and F2 alpha synthesis during exercise: effects of indomethacin and sulindac. *Med Sci Sports Exerc.* 1986; 18:678–84. [PubMed: 3537627]
138. Yamaguchi S, Inada C, Tamura M, et al. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. *Eur J Pharmacol.* 2013; 714:325–31. [PubMed: 23911885]
139. Yamada M, Sasaki R, Sato N, et al. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. *Eur J Pharmacol.* 2002; 449:167–76. [PubMed: 12163121]
140. Fujita T, Fuke Y, Satomura A, et al. PGI2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. *Prostaglandins Leukot Essent Fatty Acids.* 2001; 65:223–7. [PubMed: 11728176]
141. Siegler RL, Pysher TJ, Tesh VL, et al. Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome. *Nephron.* 2002; 92:363–8. [PubMed: 12218315]
142. Wang H, Deng JL, Yue J, et al. Prostaglandin E1 for preventing the progression of diabetic kidney disease. *Cochrane Database Syst Rev.* 2010; 12:CD006872.
143. Uemasu J, Munemura C, Fujihara M, et al. Renal response to prostaglandin E1 infusion in polycystic kidney disease versus non-polycystic renal disease. *Clin Nephrol.* 1995; 44:225–30. [PubMed: 8575121]
144. Niwa T, Asada H, Yamada K. Prostaglandin E1 infusion therapy in chronic glomerulonephritis- A double-blind, crossover trial. *Prostaglandins Leukot Med.* 1985; 19:227–33. [PubMed: 3864167]
145. Nakayama Y, Inoue T, Kohda Y, et al. Long-term observation of renal function on combination therapy with prostaglandin and angiotensin-converting enzyme inhibitor for chronic kidney disease. *Clin Nephrol.* 2008; 69:402–7. [PubMed: 18538115]
146. Ardissino G, Viganò S, Testa S, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy-report from the ItalKid Project database. *Nephrol Dial Transplant.* 2007; 22:2525–30. [PubMed: 17526542]
147. Wong CJ, Moxey-Mims M, Jerry-Fluker J. CKiD (CKD in children) prospective cohort study: a review of current findings. *Am J Kidney Dis.* 2012; 60:1002–11. [PubMed: 23022429]

Highlights

- Hyperfiltration is responsible for progression of CKD in several diseases.
- Tensile stress and fluid flow shear stress (FFSS) mediate the effects of hyperfiltration on podocytes.
- Tensile stress and FFSS induce distinct changes in podocytes via separate mechanisms.
- FFSS activates COX2-PGE₂-EP₂ axis in podocyte, osteocyte and tubular epithelial cell.
- Current therapy does not address podocyte injury that stems from FFSS in early hyperfiltration.

Figure 1.

(A) Luminal aspect of the glomerular capillary showing highly porous sieve-like structure. Capillary endothelial cell lining acts as a highly fenestrated porous filter and plasma filtrate moves to podocyte slit junctions through the basement membrane. (B) Outer aspect of the glomerular capillary showing branches from podocyte processes. These branches then further branch into foot processes that interdigitate to form slit junctions that tightly cover the capillary surface and restrict the passage of plasma macromolecules into Bowman's space. (C) Glomerular hyperfiltration damages podocytes in Bowman's space. Podocytes cover capillary loops by interdigitating foot processes. Blood flow in the capillary causes tensile stress due to circumferential stretch at the capillary bends (biaxial) in the direction of blood flow and at 90° (uniaxial) to the direction of blood flow, while the resulting flow of ultrafiltrate causes fluid flow shear stress.

Figure 2.

Prostaglandin E_2 (PGE_2) functions in an autocrine/paracrine manner through the four G-protein coupled receptors. Localization, expression and main signaling pathways of EP_1 , EP_2 , EP_3 and EP_4 are outlined.

Figure 3. Hyperfiltration, a result as well as a cause of glomerular dysfunction, can be visualized as a continuum. Overtime, net glomerular filtration rate (GFR) decreases with increasing loss of renal function, but results in increasing single nephron GFR (SNGFR) and increasing injury to podocyte structure and function from increasing tensile and shear as indicated by vertical arrows. Early effects are likely due to increased ultrafiltrate flow which is joined by tensile stress caused by increasing capillary stretch.

Figure 4.

Reduction in the number of functional nephrons occurs in many conditions and results in hyperfiltration. Hyperfiltration is considered the underlying cause of CKD leading to secondary focal segmental glomerulosclerosis (FSGS) and end-stage renal disease (ESRD). A constellation of diseases result in decreased number of functional nephrons. Congenital anomalies of kidney and urinary tract (CAKUT) including solitary kidney and low nephron number endowment are the main reasons of CKD in children. Unilateral nephrectomy for removing malignant tumors or for kidney donation causes an immediate loss of 50% of nephrons. Diabetes, hypertension or obesity may gradually lead to loss of functional nephrons. AKI due to a variety of causes may result in loss of functional nephrons.

Table 1
Urinary eicosanoids profile is altered at early stages of CKD in children born with solitary kidney

Urine samples from children with solitary kidney with normal kidney function (n=6) and from healthy children who were seen in the clinic for bedwetting (control, n=6) were analyzed. Metabolites of the COX pathway (PGE-M, PGD-M, PGI-M, TXB₂-M), LOX (LTE₄) and CYP 450 pathway (14,15-DHET, 11,12-DHET, 8,9-DHET, 20-HETE) and isoprostanes were analyzed using LC-MS/MS (ng/mgCr, Mean $\pm$ SD). Increased concentration of PGE₂ metabolite (*, p=0.14) and lower concentrations of PGI₂ metabolite (**, p=0.04) were detected. Increase in 14,15-DHET and decrease in 8-isoprotane in children with solitary kidney was statistically not significant.

	PGE-M	PGD-M	PGI-M	TXB ₂ -M	LTE ₄
Solitary Kidney (n=6)	8.9 $\pm$ 5.7*	2.3 $\pm$ 1.2	0.09 $\pm$ 0.06**	0.3 $\pm$ 0.1	0.07 $\pm$ 0.07
Control (n=6)	5.9 $\pm$ 2.5	2.0 $\pm$ 0.7	0.20 $\pm$ 0.11	0.3 $\pm$ 0.1	0.06 $\pm$ 0.06